JW THERAP-B Reports Annual Results: Loss Narrows by 5.98% to RMB 555 Million

Stock News

Mar 26

JW THERAP-B (02126) announced its annual results for the period ended December 31, 2025. The group recorded revenue of RMB 284 million, an increase of 79.3% compared to the previous year. The annual loss was RMB 555 million, narrowing by 5.98% year-on-year. The basic loss per share was RMB 1.34.

Revenue was primarily derived from (i) sales of the group's commercialized product, Relma-cel (倍诺达®), and (ii) a non-exclusive license granted to Juno for the JW sLVV production process and related technical knowledge (as well as patents). Product revenue increased by 38.4%, from RMB 158 million for the year ended December 31, 2024, to RMB 219 million for the year ended December 31, 2025. Non-exclusive license revenue recognized for the year ended December 31, 2025, amounted to RMB 64.5 million, contributing to the overall revenue growth during the reporting period.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1103083767"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1103083767\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1103083767?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 20:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1103083767","market":"sg","top_or_hot":-1,"title":"JW THERAP-B Reports Annual Results: Loss Narrows by 5.98% to RMB 555 Million","media":"Stock News","content":"<p>JW THERAP-B (02126) announced its annual results for the period ended December 31, 2025. The group recorded revenue of RMB 284 million, an increase of 79.3% compared to the previous year. The annual loss was RMB 555 million, narrowing by 5.98% year-on-year. The basic loss per share was RMB 1.34.</p>\n<p>Revenue was primarily derived from (i) sales of the group's commercialized product, Relma-cel (倍诺达®), and (ii) a non-exclusive license granted to Juno for the JW sLVV production process and related technical knowledge (as well as patents). Product revenue increased by 38.4%, from RMB 158 million for the year ended December 31, 2024, to RMB 219 million for the year ended December 31, 2025. Non-exclusive license revenue recognized for the year ended December 31, 2025, amounted to RMB 64.5 million, contributing to the overall revenue growth during the reporting period.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JW THERAP-B Reports Annual Results: Loss Narrows by 5.98% to RMB 555 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJW THERAP-B Reports Annual Results: Loss Narrows by 5.98% to RMB 555 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-26 20:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>JW THERAP-B (02126) announced its annual results for the period ended December 31, 2025. The group recorded revenue of RMB 284 million, an increase of 79.3% compared to the previous year. The annual loss was RMB 555 million, narrowing by 5.98% year-on-year. The basic loss per share was RMB 1.34.</p>\n<p>Revenue was primarily derived from (i) sales of the group's commercialized product, Relma-cel (倍诺达®), and (ii) a non-exclusive license granted to Juno for the JW sLVV production process and related technical knowledge (as well as patents). Product revenue increased by 38.4%, from RMB 158 million for the year ended December 31, 2024, to RMB 219 million for the year ended December 31, 2025. Non-exclusive license revenue recognized for the year ended December 31, 2025, amounted to RMB 64.5 million, contributing to the overall revenue growth during the reporting period.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"","article_id":"1103083767","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1103083767","pubTimestamp":1774528576,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"JW THERAP-B (02126) announced its annual results for the period ended December 31, 2025. The group recorded revenue of RMB 284 million, an increase of 79.3% compared to the previous year. The annual...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1574":"生物医药B类股","02126":"药明巨诺-B","BK1583":"高瓴概念","BK1161":"生物科技"},"translate_title":"JW THERAP-B公布全年业绩：亏损收窄5.98%至人民币5.55亿元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02126":1},"content_text":"JW THERAP-B (02126) announced its annual results for the period ended December 31, 2025. The group recorded revenue of RMB 284 million, an increase of 79.3% compared to the previous year. The annual loss was RMB 555 million, narrowing by 5.98% year-on-year. The basic loss per share was RMB 1.34.\nRevenue was primarily derived from (i) sales of the group's commercialized product, Relma-cel (倍诺达®), and (ii) a non-exclusive license granted to Juno for the JW sLVV production process and related technical knowledge (as well as patents). Product revenue increased by 38.4%, from RMB 158 million for the year ended December 31, 2024, to RMB 219 million for the year ended December 31, 2025. Non-exclusive license revenue recognized for the year ended December 31, 2025, amounted to RMB 64.5 million, contributing to the overall revenue growth during the reporting period.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}